Philanthropic Partnership Launches New Initiative Tackling Antimicrobial Resistance, the Third-Leading Cause of Death Globally, By Fast-Tracking Discovery of New Treatments
Initiative marks first investment of global health partnership between the Gates Foundation, Novo Nordisk Foundation, and Wellcome to address global health challenges that disproportionately impact people living in low- and middle-income countries
SEATTLE, COPENHAGEN, LONDON (February 12, 2025) – The Gates Foundation, Novo Nordisk Foundation, and Wellcome today announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment that will focus on combatting antimicrobial resistance (AMR) caused by a specific range of bacteria that are among the leading contributors to AMR-associated deaths. The Gr-ADI will function as a consortium where multiple funders, research institutions, and industry partners share data and work collectively to drive innovation in the discovery of urgently needed new drugs.
